BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 196.8 USD | -0.70% |
|
-3.98% | -23.95% |
| 01:51pm | Argus Adjusts Biogen's Price Target to $240 From $315 | MT |
| 01:44pm | Goldman Sachs Cuts Biogen's Price Target to $393 From $400 | MT |
Financials (USD)
| Sales 2024 * | 9.47B | Sales 2025 * | 9.59B | Capitalization | 28.81B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.89B | Net income 2025 * | 2.27B | EV / Sales 2024 * | 3.33 x |
| Net Debt 2024 * | 2.69B | Net Debt 2025 * | 288M | EV / Sales 2025 * | 3.03 x |
| P/E ratio 2024 * |
15
x | P/E ratio 2025 * |
12.7
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
| 1 day | -2.70% | ||
| 1 week | -2.79% | ||
| Current month | -8.09% | ||
| 1 month | -9.76% | ||
| 3 months | -20.13% | ||
| 6 months | -24.43% | ||
| Current year | -23.41% |
1 week
197.78
209.06
1 month
197.78221.74
Current year
197.78268.30
1 year
197.78319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | -1.52% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 14,021 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 196.8 | -0.70% | 1,159,223 |
| 24-04-12 | 198.2 | -2.70% | 1,245,896 |
| 24-04-11 | 203.7 | +1.06% | 1,019,056 |
| 24-04-10 | 201.6 | -2.41% | 901,006 |
| 24-04-09 | 206.5 | +0.77% | 969,233 |
Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
198.2
USD
Average target price
295.2
USD
Spread / Average Target
+48.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.41% | 28.81B | |
| -2.83% | 88.12B | |
| +3.95% | 40.6B | |
| +52.15% | 24.35B | |
| -4.36% | 17.5B | |
| -33.01% | 13.54B | |
| +2.68% | 13.52B | |
| -14.24% | 12.09B | |
| -5.47% | 7.88B | |
| -16.14% | 7.73B |
- Stock Market
- Equities
- BIIB Stock
